Arcus Biosciences Inc Dossier
Qualitative Analysis
Business overview
Arcus Biosciences, Inc. (NYSE: RCUS) is a clinical-stage, global biopharmaceutical company founded in 2015 and headquartered in Hayward, California. The company is dedicated to discovering, developing, and commercializing highly differentiated molecules and combination therapies for patients with cancer as well as inflammatory and autoimmune diseases. Arcus operates a capital-efficient business model heavily anchored by a deep strategic collaboration with Gilead Sciences, which provides substantial non-dilutive funding, operational support, and co-development/co-promotion rights. Its pipeline features several late-stage investigational assets, most notably casdatifan (an oral small-molecule HIF-2̱ inhibitor), quemliclustat (a small-molecule CD73 inhibitor), and zimberelimab (an anti-PD-1 antibody).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing and aggressively advancing casdatifan as a foundational standard of care in kidney cancer across multiple lines of treatment, including the Phase 3 PEAK-1 study and upcoming first-line Phase 3 trials.
Expected impact: Positions casdatifan to capture a peak sales opportunity of over $5 billion across the immunotherapy (IO)-experienced and first-line settings.
Winding down certain studies (such as the Phase 3 STAR-121 and Phase 2 EDGE-Gastric trials) and optimizing the workforce to reduce overall R&D expenses relative to historical levels.
Expected impact: Significantly reduces near-term R&D spend, preserving cash runway into at least the second half of 2028.
Expanding the company's clinical footprint beyond oncology into inflammatory and autoimmune diseases by introducing novel small-molecule candidates into clinical development.
Expected impact: Diversifies the pipeline and provides new strategic optionality and potential revenue streams outside of oncology.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides substantial financial backing, shared development costs, and commercial infrastructure to accelerate Arcus's late-stage oncology portfolio.
Terms: Includes a 10-year collaboration agreement. In January 2024, Gilead made a separate $320 million equity investment in Arcus common stock at $21.00 per share, increasing its ownership stake to approximately 33% by early 2025. Gilead also made a subsequent $14.9 million share purchase in February 2025.
Enables the evaluation of novel combination therapies, such as casdatifan plus AstraZeneca's volrustomig in the eVOLVE-RCC02 study, and domvanalimab plus durvalumab in the Phase 3 PACIFIC-8 study.
Terms: AstraZeneca sponsors and operationalizes specific joint clinical trials, reducing Arcus's direct clinical execution burden.
Grants Taiho development and commercialization rights for key Arcus molecules (including casdatifan, domvanalimab, and quemliclustat) in Japan and other Asian territories (excluding China).
Terms: Taiho operationalizes regional trials (such as PRISM-1) and participates in global trials (such as PEAK-1). Taiho's exercise of its option to casdatifan in late 2025 generated $7 million in collaboration revenue for Arcus.